Search

Displaying results 6391 - 6400 of 10000 in total
  1. Drug

    Nurulimab

    go.drugbank.com/drugs/DB18946
    Investigational

    Nurulimab is under investigation in clinical trial NCT05732805 (A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-pd-1 Compared to Anti-pd-1 Monotherapy as First-line Treatment in

  2. Drug

    Cimicoxib

    go.drugbank.com/drugs/DB05095
    Investigational

    Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia. … If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action.

  3. Drug

    Tricaine

    go.drugbank.com/drugs/DB11552
    ExperimentalVet approved

    Tricaine (as tricaine methanesulfonate) is white powder used for anesthesia, sedation, or euthanasia of fish.

  4. Drug

    ATN-161

    go.drugbank.com/drugs/DB05491
    Investigational

    expected to extend to a variety of cancers. … This approach targeting both the tumor vasculature and the cancer cells themselves, may be effective in single therapy as well as combination therapy.

  5. Drug

    AT1391

    go.drugbank.com/drugs/DB05120
    Experimental

    AT1391 is a daily insulin skin patch designed to provide continuous basal levels of insulin for patients with diabetes.

  6. Drug

    5-(5-(4-(5-hydro-4-methyl-2-oxazolyl)phenoxy)pentyl)-3-methyl isoxazole

    go.drugbank.com/drugs/DB08724
    Experimental

    These are aromatic compounds containing an ether group substituted with a benzene ring. This medication is known to target genome polyprotein. … 5-(5-(4-(5-hydro-4-methyl-2-oxazolyl)phenoxy)pentyl)-3-methyl isoxazole is a solid. This compound belongs to the phenol ethers.

  7. Drug

    Fluciclatide

    go.drugbank.com/drugs/DB14842
    Investigational

    Fluciclatide, an investigational radiotracer intended for PET imaging, was under investigation in clinical trials NCT00565721 and NCT01961583 to evaluate its ability to detect tumors and angiogenesis.

  8. Drug

    Pegsitacianine

    go.drugbank.com/drugs/DB19098
    Investigational

    Pegsitacianine is under investigation in clinical trial NCT05576974 (A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence

  9. Drug

    Saposin C

    go.drugbank.com/drugs/DB17380
    Investigational

    Saposin C is a lysosomal protein. Recombinant, non-glycosylated Saposin C is an active ingredient of BXQ-350, which is a novel, investigational anti-neoplastic therapy. … BXQ-350 consists of Saposin C and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes.

  10. Drug

    SynOV1.1

    go.drugbank.com/drugs/DB17539
    Investigational

    SynOV1.1 is an investigational cancer immunotherapy developed by SyngenTech. … It is a recombinant oncolytic adenovirus, controlled by synthetic gene circuit, encoding the human immunostimulating factor cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF).